BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kattakuzhy S, Levy R, Rosenthal E, Tang L, Wilson E, Kottilil S. Hepatitis C genotype 3 disease. Hepatol Int 2016;10:861-70. [DOI: 10.1007/s12072-016-9748-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Chua JV, Kottilil S. Sofosbuvir and velpatasvir: a stellar option for patients with decompensated hepatitis C virus (HCV) cirrhosis. Ann Transl Med 2016;4:S8. [PMID: 27867976 DOI: 10.21037/atm.2016.08.56] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
2 El‐serag HB. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 758-72. [DOI: 10.1002/9781119436812.ch59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
3 Green V, Roytman M, Komatsu H. Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review. Case Reports in Hepatology 2022;2022:1-5. [DOI: 10.1155/2022/3556780] [Reference Citation Analysis]
4 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lee R, Kottilil S, Wilson E. Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. Hepatol Int 2017;11:161-70. [PMID: 27928718 DOI: 10.1007/s12072-016-9776-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
6 Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017;24:1073274817729245. [PMID: 28975830 DOI: 10.1177/1073274817729245] [Cited by in Crossref: 155] [Cited by in F6Publishing: 157] [Article Influence: 38.8] [Reference Citation Analysis]
7 Fernandes Campos GR, Ward J, Chen S, Bittar C, Vilela Rodrigues JP, Martinelli ALC, Souza FF, Pereira LRL, Rahal P, Harris M. A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir. J Gen Virol 2021;102. [PMID: 33141008 DOI: 10.1099/jgv.0.001496] [Reference Citation Analysis]
8 Gitto S, Gamal N, Andreone P. NS5A inhibitors for the treatment of hepatitis C infection. J Viral Hepat 2017;24:180-6. [DOI: 10.1111/jvh.12657] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
9 Hu L, Li J, Cai H, Yao W, Xiao J, Li YP, Qiu X, Xia H, Peng T. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles. Antiviral Res 2017;148:5-14. [PMID: 29074218 DOI: 10.1016/j.antiviral.2017.10.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Bhushan A, Ghosh S, Bhattacharjee S, Chinnaswamy S. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection. J Interferon Cytokine Res 2017;37:369-82. [PMID: 28727946 DOI: 10.1089/jir.2017.0002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
11 Chan A, Patel K, Naggie S. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs 2017;77:131-44. [PMID: 28074358 DOI: 10.1007/s40265-016-0685-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
12 Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. Eur J Health Econ 2018;19:37-44. [PMID: 28008546 DOI: 10.1007/s10198-016-0865-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Abbas Z, Saad M, Nadeem R, Jawed F, Abbas M. Sofosbuvir and Ribavirin With or Without Pegylated Interferon for Hepatitis C Genotype 3: A Real World Experience. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.45525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
14 Ward JC, Bowyer S, Chen S, Fernandes Campos GR, Ramirez S, Bukh J, Harris M. Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon. J Gen Virol 2020;101:1182-90. [PMID: 32897181 DOI: 10.1099/jgv.0.001486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int 2018;12:214-22. [PMID: 29845496 DOI: 10.1007/s12072-018-9873-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
16 de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis 2017;5:Doc08. [PMID: 30671330 DOI: 10.3205/id000034] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
17 Capileno YA, Van den Bergh R, Donchunk D, Hinderaker SG, Hamid S, Auat R, Khalid GG, Fatima R, Yaqoob A, Van Overloop C. Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan. PLoS One 2017;12:e0175562. [PMID: 28448576 DOI: 10.1371/journal.pone.0175562] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
18 de Leuw P, Stephan C. Protease inhibitor therapy for hepatitis C virus-infection. Expert Opin Pharmacother 2018;19:577-87. [PMID: 29595065 DOI: 10.1080/14656566.2018.1454428] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
19 Dar GA, Yattoo GN, Gulzar GM, Sodhi JS, Gorka S, Laway MA. Treatment of Chronic Hepatitis C Genotype 3 With Ledipasvir and Sofosbuvir: An Observational Study. J Clin Exp Hepatol 2021;11:227-31. [PMID: 33746448 DOI: 10.1016/j.jceh.2020.06.011] [Reference Citation Analysis]
20 Trucchi C, Orsi A, Alicino C, Sticchi L, Icardi G, Ansaldi F. State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res 2016;2016:1412840. [PMID: 27843956 DOI: 10.1155/2016/1412840] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
21 Morisco F, Granata R, Camera S, Ippolito A, Milella M, Conti F, Masetti C, Smedile A, Tundo P, Santantonio T, Valvano MR, Termite A, Gatti P, Messina V, Iacobellis A, Librandi M, Caporaso N, Andriulli A; ITAL-C consortium. Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. United European Gastroenterol J 2018;6:225-37. [PMID: 29511552 DOI: 10.1177/2050640617717158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]